Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17331344,C(max),"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[μg] / [l],17.0,12040,DB00022,Peginterferon alfa-2b
,17331344,C(max),"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[μg] / [l],18,12041,DB00022,Peginterferon alfa-2b
,17331344,C(max),"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[μg] / [l],7.4,12042,DB00022,Peginterferon alfa-2b
,17331344,AUC,"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[h·μg] / [ml],0.036,12043,DB00022,Peginterferon alfa-2b
,17331344,AUC,"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[h·μg] / [ml],0.033,12044,DB00022,Peginterferon alfa-2b
,17331344,AUC,"Non-pegylated and pegylated IFN-alpha both increased DTX oral bioavailability parameters: C(max) (17.0+/-4.0 microg L(-1) (P < 0.02) and 18+/-5.5 microg L(-1) (P < 0.05), respectively, vs 7.4+/-2.5 microg L(-1) for the control) and AUC (0.036+/-0.010 microg h mL(-1) (P < 0.01) and 0.033+/-0.009 microg h mL(-1) (P < 0.01), respectively, versus 0.012+/-0.004 microg h mL(-1) for the control).","Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331344/),[h·μg] / [ml],0.012,12045,DB00022,Peginterferon alfa-2b
,24093213,MTD,The MTD of cyclical oral TMZ was 100 mg/m² on days 1-7 and 15-21 when combined with weekly subcutaneous PEG-IFNα-2b at 1.5 mcg/kg/week on 28 days cycles.,"A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24093213/),[mg] / [m²],100,15027,DB00022,Peginterferon alfa-2b
,16939523,clearance,The clearance at treatment week 4 was 42.3 l day(-1) (patients with CLcr 120 ml min(-1)) with interpatient variability 30%.,Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16939523/),[l] / [day],42.3,29030,DB00022,Peginterferon alfa-2b
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.748,40515,DB00022,Peginterferon alfa-2b
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.733,40516,DB00022,Peginterferon alfa-2b
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.999,40517,DB00022,Peginterferon alfa-2b
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],1.616,40518,DB00022,Peginterferon alfa-2b
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],1.788,40519,DB00022,Peginterferon alfa-2b
,24092661,Ctrough levels,"The mean telaprevir Ctrough levels at days 3, 7 and 14 of SVR patients (2.748, 2.733 and 2.999 μg/mL, respectively) were significantly higher than those of non-SVR patients (1.616, 1.788 and 2.314 μg/mL, respectively) (all P < 0.05).",Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092661/),[μg] / [ml],2.314,40520,DB00022,Peginterferon alfa-2b
,29301580,Tmax,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,73,43973,DB00022,Peginterferon alfa-2b
,29301580,Tmax,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,54,43974,DB00022,Peginterferon alfa-2b
,29301580,MRT,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,133,43975,DB00022,Peginterferon alfa-2b
,29301580,MRT,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,115,43976,DB00022,Peginterferon alfa-2b
,29301580,ke,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),1/[h],0.011,43977,DB00022,Peginterferon alfa-2b
,29301580,ke,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),1/[h],0.013,43978,DB00022,Peginterferon alfa-2b
,29301580,t1/2,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,192,43979,DB00022,Peginterferon alfa-2b
,29301580,t1/2,Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]).,Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29301580/),h,108,43980,DB00022,Peginterferon alfa-2b
,18240868,viral decline,"After 4 weeks of treatment, there was a median viral decline of 2.94 log10 copies/ml in those treated with PEG-IFN-alpha2b and lamivudine and only 0.45 log10 copies/ml in the PEG-IFN-alpha2b monotherapy group.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),,2.94,85918,DB00022,Peginterferon alfa-2b
,18240868,maximal,"Modelling of pharmacokinetics and viral kinetics data in this group revealed that viral load was minimal 3.6 days after PEG-IFN-alpha2b administration, the mean maximal and mean antiviral effectiveness was 70% and 48% with a mean infected cell loss rate of 0.07 per day, while no significant biphasic decline was observed.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),%,70,85919,DB00022,Peginterferon alfa-2b
,18240868,anti,"Modelling of pharmacokinetics and viral kinetics data in this group revealed that viral load was minimal 3.6 days after PEG-IFN-alpha2b administration, the mean maximal and mean antiviral effectiveness was 70% and 48% with a mean infected cell loss rate of 0.07 per day, while no significant biphasic decline was observed.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),%,70,85920,DB00022,Peginterferon alfa-2b
,18240868,anti,"Modelling of pharmacokinetics and viral kinetics data in this group revealed that viral load was minimal 3.6 days after PEG-IFN-alpha2b administration, the mean maximal and mean antiviral effectiveness was 70% and 48% with a mean infected cell loss rate of 0.07 per day, while no significant biphasic decline was observed.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),%,48,85921,DB00022,Peginterferon alfa-2b
,18240868,infected cell loss rate,"Modelling of pharmacokinetics and viral kinetics data in this group revealed that viral load was minimal 3.6 days after PEG-IFN-alpha2b administration, the mean maximal and mean antiviral effectiveness was 70% and 48% with a mean infected cell loss rate of 0.07 per day, while no significant biphasic decline was observed.",Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240868/),1/[d],0.07,85922,DB00022,Peginterferon alfa-2b
,23975236,body surface area normalized apparent clearance,"The mean body surface area normalized apparent clearance of PEG-IFN alfa-2b was 0.56 L/h/m(2), and was similar when evaluated across the pediatric age groups.",Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23975236/),[h·l] / [m(2],0.56,92176,DB00022,Peginterferon alfa-2b
,17501760,t(1/2),"C(max) of PEG-IFN occurred 12-48 h after the initial administration, with t(1/2) and C(min) being 49 h and 190 pg/mL, respectively.",Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17501760/),h,49,105350,DB00022,Peginterferon alfa-2b
,17501760,C(min),"C(max) of PEG-IFN occurred 12-48 h after the initial administration, with t(1/2) and C(min) being 49 h and 190 pg/mL, respectively.",Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17501760/),[pg] / [ml],190,105351,DB00022,Peginterferon alfa-2b
,20509027,T (max),"Peginterferon α-2b was well-absorbed following SC administration, with a median T (max) of 24 h.",Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),h,24,114159,DB00022,Peginterferon alfa-2b
,20509027,half-life,Mean half-life estimates ranged from 43 to 51 h.,Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),h,43 to 51,114160,DB00022,Peginterferon alfa-2b
,20509027,accumulation factor,The accumulation factor was 1.69 after induction therapy.,Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),,1.69,114161,DB00022,Peginterferon alfa-2b
,17555463,maximum serum concentration,"Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml(-1); 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml(-1); 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg(-1)vs. 1.28 l kg(-1), respectively).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),[pg] / [ml],1305.8,115743,DB00022,Peginterferon alfa-2b
,17555463,maximum serum concentration,"Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml(-1); 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml(-1); 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg(-1)vs. 1.28 l kg(-1), respectively).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),[pg] / [ml],731.4,115744,DB00022,Peginterferon alfa-2b
,17555463,apparent volume of distribution,"Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml(-1); 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml(-1); 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg(-1)vs. 1.28 l kg(-1), respectively).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),[l] / [kg],0.80,115745,DB00022,Peginterferon alfa-2b
,17555463,apparent volume of distribution,"Mean maximum serum concentration was almost doubled in patients with severe insufficiency [1305.8 pg ml(-1); 95% confidence interval (CI) 825, 1786] compared with subjects with normal renal function (731.4 pg ml(-1); 95% CI 407, 1056), whereas the apparent volume of distribution was reduced (0.80 l kg(-1)vs. 1.28 l kg(-1), respectively).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),[l] / [kg],1.28,115746,DB00022,Peginterferon alfa-2b
,17555463,Elimination half-life,"Elimination half-life was extended in patients with moderate and severe renal insufficiency (65.6 h and 64.9 h, respectively) compared with subjects with normal renal function (51.5 h).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),h,65.6,115747,DB00022,Peginterferon alfa-2b
,17555463,Elimination half-life,"Elimination half-life was extended in patients with moderate and severe renal insufficiency (65.6 h and 64.9 h, respectively) compared with subjects with normal renal function (51.5 h).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),h,64.9,115748,DB00022,Peginterferon alfa-2b
,17555463,Elimination half-life,"Elimination half-life was extended in patients with moderate and severe renal insufficiency (65.6 h and 64.9 h, respectively) compared with subjects with normal renal function (51.5 h).",Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555463/),h,51.5,115749,DB00022,Peginterferon alfa-2b
,14671645,serum half-life,Polyethylene glycol-modified rIFN-alpha2b is a novel formulation with a serum half-life ( approximately 40 h) compatible with once-weekly dosing.,Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671645/),h,40,143181,DB00022,Peginterferon alfa-2b
,14671645,MCR rates,The MCR rates were 23% for pegylated rIFN-alpha2b vs 28% for rIFN-alpha2b in the primary efficacy analysis and 26 vs 28% in the prospectively modified efficacy analysis.,Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671645/),%,23,143182,DB00022,Peginterferon alfa-2b
,14671645,MCR rates,The MCR rates were 23% for pegylated rIFN-alpha2b vs 28% for rIFN-alpha2b in the primary efficacy analysis and 26 vs 28% in the prospectively modified efficacy analysis.,Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671645/),%,28,143183,DB00022,Peginterferon alfa-2b
,14671645,MCR rates,The MCR rates were 23% for pegylated rIFN-alpha2b vs 28% for rIFN-alpha2b in the primary efficacy analysis and 26 vs 28% in the prospectively modified efficacy analysis.,Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671645/),%,26,143184,DB00022,Peginterferon alfa-2b
,33725322,time to reach the median maximum serum concentration,The time to reach the median maximum serum concentration was similar between ethnicities (approximately 96-111 h).,Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33725322/),h,96-111,153901,DB00022,Peginterferon alfa-2b
,33725322,terminal half-life,The terminal half-life was 48-57 h in Japanese subjects and 31-75 h in Caucasian subjects.,Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33725322/),h,48-57,153902,DB00022,Peginterferon alfa-2b
,33725322,terminal half-life,The terminal half-life was 48-57 h in Japanese subjects and 31-75 h in Caucasian subjects.,Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33725322/),h,31-75,153903,DB00022,Peginterferon alfa-2b
,16761329,EC50,"Although PEG-IFN concentrations and pharmacokinetic parameters were similar in sustained virological responders (SVRs) and nonresponders (NRs), the PEG-IFN alpha-2b concentration that decreases HCV production by 50% (EC50) was lower in SVRs compared with NRs (0.04 vs. 0.45 microg/L [P = .014]).",Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16761329/),[μg] / [l],0.04,197816,DB00022,Peginterferon alfa-2b
,16761329,EC50,"Although PEG-IFN concentrations and pharmacokinetic parameters were similar in sustained virological responders (SVRs) and nonresponders (NRs), the PEG-IFN alpha-2b concentration that decreases HCV production by 50% (EC50) was lower in SVRs compared with NRs (0.04 vs. 0.45 microg/L [P = .014]).",Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16761329/),[μg] / [l],0.45,197817,DB00022,Peginterferon alfa-2b
,18178958,overall response rate,"In all, 116 patients were assessable for response: 2 (1.7%) had a complete response and 19 (16.4%) a partial response (overall response rate 18.1%).",Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),%,18.1,210574,DB00022,Peginterferon alfa-2b
,18178958,Overall survival,Overall survival was 9.4 months; PFS was 2.8 months.,Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),month,9.4,210575,DB00022,Peginterferon alfa-2b
,18178958,PFS,Overall survival was 9.4 months; PFS was 2.8 months.,Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18178958/),month,2.8,210576,DB00022,Peginterferon alfa-2b
,21092287,AUC,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),[h·pg] / [ml],53623,235787,DB00022,Peginterferon alfa-2b
,21092287,AUC,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),[h·pg] / [ml],44311,235788,DB00022,Peginterferon alfa-2b
,21092287,Cmax,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),[pg] / [ml],333,235789,DB00022,Peginterferon alfa-2b
,21092287,Cmax,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),[pg] / [ml],271,235790,DB00022,Peginterferon alfa-2b
,21092287,Tmax,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),h,54,235791,DB00022,Peginterferon alfa-2b
,21092287,Tmax,"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),h,55,235792,DB00022,Peginterferon alfa-2b
,21092287,half-life (t1/2),"In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs.","Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),,72.4,235793,DB00022,Peginterferon alfa-2b
,21092287,terminal elimination rate (lambda),64.8 h; terminal elimination rate (lambda): 0.011 vs. 0.014 h(-1); mean residence time (MRT): 135 vs.,"Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),1/[h],0.011,235794,DB00022,Peginterferon alfa-2b
,21092287,terminal elimination rate (lambda),64.8 h; terminal elimination rate (lambda): 0.011 vs. 0.014 h(-1); mean residence time (MRT): 135 vs.,"Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),1/[h],0.014,235795,DB00022,Peginterferon alfa-2b
,21092287,mean residence time (MRT),64.8 h; terminal elimination rate (lambda): 0.011 vs. 0.014 h(-1); mean residence time (MRT): 135 vs.,"Pharmacokinetic and pharmacodynamic comparison of two ""pegylated"" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092287/),,135,235796,DB00022,Peginterferon alfa-2b
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,47.30,238596,DB00022,Peginterferon alfa-2b
,20923249,terminal elimination half-life,The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.,Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923249/),h,33.23,238597,DB00022,Peginterferon alfa-2b
,12934165,absorption half-life,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,2.3,262256,DB00022,Peginterferon alfa-2b
,12934165,absorption half-lives,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,50,262257,DB00022,Peginterferon alfa-2b
,12934165,absorption half-lives,"The absorption half-life of standard interferon alfa is 2.3 hours, while absorption half-lives for peginterferon alfa-2a and alfa-2b are 50 hours and 4.6 hours, respectively.",Pharmacokinetics of peginterferons. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12934165/),h,4.6,262258,DB00022,Peginterferon alfa-2b
